雷莫芦单抗在肿瘤分子靶向治疗中的应用进展

发布时间：2018-04-25 03:26

本文选题：雷莫芦单抗 + 血管内皮生长因子　；参考：《中国药房》2017年11期

【摘要】：目的:了解雷莫芦单抗在肿瘤分子靶向治疗中的研究进展。方法:查阅近年来国内外相关文献,对雷莫芦单抗的作用机制、药动学特征、临床研究、不良反应等进行归纳和总结。结果与结论:雷莫芦单抗是一种全人源化免疫球蛋白1单克隆抗体,可特异性地与血管内皮生长因子受体2结合后诱导其构象和空间位阻变化,干扰其与配体结合,抑制新生血管的形成,阻断肿瘤细胞的血液供应,导致肿瘤细胞凋亡。雷莫芦单抗药动学特征符合非线性药动学特点,且消除机制存在饱和现象。目前,已开展雷莫芦单抗用于非小细胞肺癌、胃癌、胃-食管结合部腺癌、转移性结直肠癌、原发性肝癌、肾细胞癌、乳腺癌、卵巢上皮性肿瘤、转移性去势抵抗性前列腺癌、黑色素瘤、复发性胶质母细胞瘤、膀胱上皮癌、胆管癌和胰腺癌等肿瘤的临床研究。雷莫芦单抗的不良反应在可耐受范围内。
[Abstract]:Objective: to understand the progress in the research of Lei Mo's reuzumab in the molecular targeting therapy of tumor. Methods: to refer to the relevant literature at home and abroad in recent years and to summarize and summarize the mechanism of action, pharmacokinetics, clinical research and adverse reactions of Lei Mo reab. Results and conclusion: Lei Mo is a monoclonal antibody to all human immunoglobulin 1. In vivo, the conformation and spatial resistance changes are induced specifically with vascular endothelial growth factor receptor 2, which interferes with the binding of the ligand to the ligand, inhibits the formation of the neovascularization, blocks the blood supply of the tumor cells, and leads to the apoptosis of the tumor cells. Phenomenon. At present, reulmur monoclonal antibody has been used in non small cell lung cancer, gastric cancer, gastric to esophagus junction adenocarcinoma, metastatic colorectal cancer, primary liver cancer, renal cell carcinoma, breast cancer, ovarian epithelial tumor, metastatic castration resistant prostate cancer, melanoma, recurrent glioblastoma, bladder epithelial cancer, cholangiocarcinoma and pancreatic cancer. Clinical study of tumor. The adverse reaction of Remo mAb is within tolerance.

【作者单位】：吉林大学第一医院药学部;
【分类号】：R979.1

【相似文献】